secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039391
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen Q2 net loss $19.5M; cash $147M; FDA clinical hold on DM1 trial continues
-------------------------------------------------------------------------------

- Net loss of $19.5M for Q2 2023 vs $17.3M YoY; R&D expense $16.9M, G&A $4.2M.
- Cash and equivalents $147.0M as of June 30, 2023; runway into early 2025.
- FDA clinical hold remains on IND for PGN-EDODM1 Phase 1 study; working to lift.
- Phase 2 CONNECT1-EDO51 open-label MAD study dosing patients in Canada H2 2023.
- Phase 2 CONNECT2-EDO51 multinational RCT expected to initiate H2 2023; initial data mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023039391/0000950170-23-039391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023039391/pepg-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer